Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIVING: Lopinavir Pellets for Pediatric HIV
NCT02346487Phase 3Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Sep 2015
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV), sponsored by Drugs for Neglected Diseases initiative. Primary endpoint: Treatment effectiveness at 48 weeks. Started Sep 2015; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02346487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346487.